Halozyme withdraws $2.1 billion buyout offer for German drug developer Evotec

By Yahoo! Finance | Nov 22, 2024 at 12:02 PM EST

Halozyme Therapeutics withdraws its bid to acquire Evotec SE for 2 billion euros due to lack of engagement. Evotec remains focused on its standalone strategy for growth and profitability, despite interest from potential buyers. Stocks react with Halozyme rising and Evotec falling.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.